We are live on ! Find out more
VTGN icon

VistaGen Therapeutics
VTGN

106 hedge funds and large institutions have $269M invested in VistaGen Therapeutics in 2021 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 39 increasing their positions, 29 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

34% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 29

18% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 11

2% more funds holding

Funds holding: 104 → 106 (+2)

0.03% more ownership

Funds ownership: 2.27% → 2.31% (+0.03%)

25% less capital invested

Capital invested by funds: $360M → $269M (-$91.2M)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

93% less call options, than puts

Call options by funds: $73K | Put options by funds: $1.04M

Holders
106
Holders Change
+2
Holders Change %
+1.92%
% of All Funds
1.63%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
13
Increased
39
Reduced
29
Closed
11
Calls
$73K
Puts
$1.04M
Net Calls
-$966K
Net Calls Change
-$312K

Top Buyers

Rank Fund Capital Flow
1
CC
Commodore Capital
New York
+$7.25M
2
LGM
Logos Global Management
California
+$4.34M
3
NIP
Nicholas Investment Partners
California
+$3.26M
4
State Street
State Street
Massachusetts
+$1.62M
5
Bank of America
Bank of America
North Carolina
+$1.16M

Top Sellers

Rank Fund Capital Flow
1
EI
EAM Investors
California
-$2.31M
2
Victory Capital Management
Victory Capital Management
Texas
-$2.18M
3
EGI
EAM Global Investors
California
-$1.74M
4
Two Sigma Investments
Two Sigma Investments
New York
-$1.4M
5
Millennium Management
Millennium Management
New York
-$943K
Name Holding Trade Value Shares
Change 		Change in
Stake
IC
26
Ikarian Capital
Texas
$927K -$271K -4,167 -21%
Two Sigma Investments
27
Two Sigma Investments
New York
$920K -$1.4M -21,565 -58%
UBS Group
28
UBS Group
Switzerland
$871K +$507K +7,786 +110%
SCM
29
Silverarc Capital Management
Massachusetts
$827K -$615K -9,452 -40%
Citigroup
30
Citigroup
New York
$804K +$515K +7,916 +136%
SSA
31
Schonfeld Strategic Advisors
New York
$753K -$78.7K -1,210 -9%
New York State Common Retirement Fund
32
New York State Common Retirement Fund
New York
$716K +$505K +7,763 +174%
Morgan Stanley
33
Morgan Stanley
New York
$669K +$632K +9,715 +561%
CAM
34
ClariVest Asset Management
California
$563K -$10.4K -160 -2%
Susquehanna International Group
35
Susquehanna International Group
Pennsylvania
$504K +$131K +2,008 +30%
State of Wisconsin Investment Board
36
State of Wisconsin Investment Board
Wisconsin
$482K – – –
Barclays
37
Barclays
United Kingdom
$459K +$339K +5,203 +197%
AA
38
ALPS Advisors
Colorado
$451K -$11.5K -177 -2%
BWM
39
Bulltick Wealth Management
Florida
$436K +$290K +4,450 +149%
OFA
40
Oak Family Advisors
Illinois
$360K +$18K +277 +5%
Wells Fargo
41
Wells Fargo
California
$356K +$210K +3,225 +113%
RhumbLine Advisers
42
RhumbLine Advisers
Massachusetts
$306K -$7.03K -108 -2%
Principal Financial Group
43
Principal Financial Group
Iowa
$291K +$242K +3,726 +300%
HighTower Advisors
44
HighTower Advisors
Illinois
$266K – – –
Citadel Advisors
45
Citadel Advisors
Florida
$266K +$21.4K +329 +8%
RCG
46
Rock Creek Group
District of Columbia
$263K +$351K +5,386 New
DADC
47
D.A. Davidson & Co
Montana
$249K – – –
Deutsche Bank
48
Deutsche Bank
Germany
$244K +$13.5K +207 +5%
California State Teachers Retirement System (CalSTRS)
49
California State Teachers Retirement System (CalSTRS)
California
$208K +$7.35K +113 +3%
AIG
50
American International Group
New York
$201K -$6.7K -103 -3%
1
2
3 4 5

VTGN Hedge Fund Activity: Q4 2021 in Review

106 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in VistaGen Therapeutics (VTGN) for Q4 2021, worth a combined $269M — down 25% from $360M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new VTGN positions and 11 closed out — a net gain of 2 holders — while 39 added to existing stakes and 29 trimmed.

The largest buyer was Commodore Capital, adding an estimated $7.25M. The largest seller was EAM Investors, exiting entirely with an estimated $2.31M sold.

  • 106 institutional investors held VistaGen Therapeutics (VTGN) as of Q4 2021, up from 104 in Q3 2021.
  • Funds reported $269M of VistaGen Therapeutics stock for Q4 2021, down 25% quarter-over-quarter.
  • 13 funds opened new VistaGen Therapeutics positions in Q4 2021 and 11 closed out, a net change of +2 holders.
  • The largest VistaGen Therapeutics buyer in Q4 2021 was Commodore Capital, an estimated $7.25M added.
  • The largest VistaGen Therapeutics seller in Q4 2021 was EAM Investors, an estimated $2.31M sold.

Based on aggregated 13F filings for Q4 2021.